Avant Diagnostics 10-Q 23 May 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Mar. 31, 2016	May. 23, 2016
Document And Entity Information
Entity Registrant Name	Avant Diagnostics, Inc.
Entity Central Index Key	1,451,929
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		215,354,543
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,016

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Current assets:
Cash	$ 215,158	$ 43,635
Prepaid expenses		42
Total current assets	$ 215,158	$ 43,677
Other assets:
Deposit on asset acquisition	40,000
Intellectual property	1,664,799	$ 1,651,875
Website development cost, net	20,188
Patent costs, net	128,862	$ 143,178
Total assets	2,069,007	1,838,730
Current liabilities:
Accounts payable	186,362	159,598
Accrued payroll & benefits	80,000	$ 320,000
Accrued interest	3,407
Due to related party	90,217	$ 141,717
Convertible Notes Payable, net of unamortized discount of $59,010 and $0 at March 31, 2016 and September 30, 2015, respectively.	153,490
Derivative liabilities	51,828
Total current liabilities	$ 565,304	$ 621,315
Commitments and contingencies
STOCKHOLDERS' EQUITY:
Preferred stock, $0.001 par value; 50,000,000 shares authorized, Series B preferred stock, $0.001 par value; 3,000 shares authorized, -0- shares issued and outstanding as of December 31, 2015 and September 30, 2015
Common stock, $0.00001 par value, 450,000,000 shares authorized; 110,204,543 and 95,944,743 shares issued; 108,654,543 and 95,162,243 outstanding as of March 31, 2016 and September 30, 2015, respectively	$ 1,102	$ 959
Additional paid in capital	11,748,967	11,030,534
Accumulated deficit	(10,246,366)	(9,814,078)
Total stockholders' equity	1,503,703	1,217,415
Total liabilities and stockholders' equity	$ 2,069,007	$ 1,838,730

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Condensed Consolidated Balance Sheets Parenthetical
Convertible Notes Payable	$ 59,010	$ 0
STOCKHOLDERS' EQUITY:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Series B preferred stock, par value	$ 0.001	$ 0.001
Series B preferred stock, shares authorized	3,000	3,000
Series B Preferred stock, shares issued	0	0
Series B Preferred stock, shares outstanding	0	0
Common Stock, par value	$ 0.00001	$ 0.00001
Common Stock, shares authorized	450,000,000	450,000,000
Common Stock, shares issued	110,204,543	95,944,743
Common Stock, shares outstanding	108,654,543	95,162,243

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
OPERATING EXPENSES:
Selling, general and administrative	$ 174,928	$ 118,334	$ 305,313	$ 279,302
Professional fees	$ 51,100	60,758	$ 118,250	60,758
Merger costs		641,126		641,126
Total operating expenses	$ 226,028	820,218	$ 423,563	981,186
Loss from operations	(226,028)	$ (820,218)	(423,563)	$ (981,186)
Other income (expense):
Interest expense	(13,846)		(13,846)
Gain on change in fair value of derivative liabilities	5,121		5,121
NET LOSS	$ (234,753)	$ (820,218)	$ (432,288)	$ (981,186)
Net loss, basic and diluted	$ 0	$ (0.01)	$ 0	$ (0.01)
Weighted average number of common shares, basic and diluted	100,123,242	77,974,136	97,071,245	77,048,737
Comprehensive loss:
Net loss	$ (234,753)	$ (820,218)	$ (432,288)	$ (981,186)
Unrealized losses on available for sale securities		(100,000)		(700,000)
Comprehensive loss	$ (234,753)	$ (920,218)	$ (432,288)	$ (1,681,186)

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF CHANGES STOCKHOLDERS' EQUITY (Unaudited) - 6 months ended Mar. 31, 2016 - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Sep. 30, 2015	$ 959	$ 11,030,534	$ (9,814,078)	$ 1,217,415
Beginning Balance, Shares at Sep. 30, 2015	95,944,743
Sale of common stock, Amount	$ 48	234,952		235,000
Sale of common stock, Shares	4,700,000
Stock based compensation, Amount	$ 10	54,991		55,001
Stock based compensation, Shares	990,000
Conversion of accrued officer salary to common stock, Amount	$ 85	$ 428,490		428,575
Conversion of accrued officer salary to common stock, Shares	8,569,800
Net loss			$ (432,288)	(432,288)
Ending Balance, Amount at Mar. 31, 2016	$ 1,102	$ 11,748,967	$ (10,246,366)	$ 1,503,703
Ending Balance, Shares at Mar. 31, 2016	110,204,543

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (432,288)	$ (981,186)
Adjustment to reconcile net loss to net cash used in operating activities:
Amortization of patent and web design costs	15,379
Amortization of debt discounts	$ 10,439
Merger costs		$ 641,126
Stock based compensation	$ 55,001	$ 3,579
Gain on change in fair value of derivative liabilities	(5,121)
Changes in operating assets and liabilities:
Prepaid expenses	127	$ (30)
Accounts payable	26,765	(40,376)
Accrued expenses-related party	36,990	244,980
Accrued liabilities	103,407	12,575
Net cash used in operating activities	(189,301)	(119,332)
CASH FLOWS FROM INVESTING ACTIVITIES:
License costs	(12,924)	$ (59,378)
Website development	(21,252)
Deposit on acquisition	(40,000)
Net cash used in investing activities	(74,176)	$ (59,378)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock, net	$ 235,000	340,000
Proceeds from warrant and option exercises		$ 1,300
Proceeds from convertible notes payable	$ 200,000
Net cash provided by financing activities	435,000	$ 341,300
Net increase in cash	171,523	162,590
Cash, beginning of period	43,635	6,000
Cash, end of period	$ 215,158	$ 168,590
SUPPLEMENTAL INFORMATION:
Cash paid during period for: Interest
Cash paid during period for: Income taxes
Non-cash investing and financing activities:
Net liabilities assumed in connection with recapitalization		$ 70,000
Effect of recapitalization		$ 71,384
Shares issued in settlement of related party accrued salary and other current liabilities	$ 428,575
Initial fair value of derivative liabilities	$ 56,949

NATURE OF OPERATIONS AND BASIS

NATURE OF OPERATIONS AND BASIS OF PRESENTATION	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION	Avant Diagnostics, Inc. ("Avant", "we" or the "Company"), a Nevada corporation established in 2009, is a diagnostic company that focuses on the commercialization of a series of proprietary microarray-based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe disease states. Avant was originally named Arrayit Diagnostics, Inc. which was formed as a majority owned subsidiary of Arrayit Corporation ("Arrayit") through a technology transfer in July 2009. In January 2013, the Company effected a name change to Avant Diagnostics, Inc. The Company's premier product is OvaDxÒ, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The Company believes this test will be approved by the U.S. Food and Drug Administration ("FDA") as the first pre-symptomatic screening test for ovarian cancer in the United States, (although there can be no assurance that approval will be obtained), detecting all types and all stages of ovarian cancer with high sensitivity and specificity. The Company's primary activities since inception has been focused preparing sample specimens in order for OvaDx to obtain FDA approval. The Company has not generated revenues since inception. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of March 31, 2016 and the condensed consolidated results of its operations and cash flows for the for the three and six months ended March 31, 2016. The results of operations for the three and six months ended March 31, 2016 are not necessarily indicative of the operating results for the full year ending September 30, 2016, or any other period. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related disclosures of the Company as of September 30, 2015 and for the year then ended, which was filed with the Securities and Exchange Commission on Form 10-K on January 13, 2016.

GOING CONCERN AND MANAGEMENT'S

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	Since inception, the Company has financed its operations primarily through equity and debt financings and advances from related parties. As of March 31, 2016, the Company had an accumulated deficit of $10,246,366. During the six months ended March 31, 2016 and 2015, the Company incurred net losses of $432,288 and $981,186, respectively, and used cash in operating activities of $189,301 and $119,332, respectively. These conditions raise substantial doubt about the Company's ability to continue as a going concern. See note #9- Subsequent Events for detail on acquisitions of Amarantus Diagnostics Inc. and Theranostics Health, Inc. The Company recognizes it will need to raise additional capital in order to fund operations, meet its payment obligations and execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will generate revenues, become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds on favorable terms, it will have to develop and implement a plan to further extend payables and to raise capital through the issuance of debt or equity on less favorable terms until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. If the Company is unable to obtain financing on a timely basis, the Company could be forced to sell its assets, discontinue its operations and/or pursue other strategic avenues to commercialize its technology, and its intellectual property could be impaired.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, ALP. All intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates include the valuation of derivative liabilities, useful lives of long-lived assets, the valuation of debt and equity instruments and the valuation allowance relating to stock based compensation and the Company's deferred tax assets. Actual results could differ from those estimates. Net Loss per Share of Common Stock The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period, and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the "treasury stock" and/or "if converted" methods as applicable. The computation of basic and diluted loss per share for the six months ended March 31, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: March 31, 2016 March 31, 2015 Shares issued upon conversion of convertible notes 3,125,000 - Intangible Assets The Company's intangible assets consist of intellectual property for the technology transfer agreement and licensing payments for use of various patent for its worldwide exclusive licensed rights to OvaDx, a diagnostic screening test for the early detection of ovarian cancer. As of March 31, 2016 the Company has not yet received FDA approval with respect to the clinical use of these intangible assets. Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company's intangible asset with a finite life is the patent costs, which are being amortized over their economic or legal life, whichever is shorter. The estimated life is 15 years, amortized ratably. To date, these patent costs are due to legal, filing issuance and maintenance fees associated with the patents. The amortization expense was $5,379 and $15,379 for the three and six months ended March 31, 2016, respectively. Impairment of Long-Lived Assets The Company reviews the carrying value of intangibles and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair value. Management performed an evaluation of its intangible assets as of March 31, 2016 and no impairment was deemed to exist. Considerable management judgment is necessary to estimate the fair value. Accordingly, actual results could vary significantly from management's estimates. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the condensed consolidated statements of operations and comprehensive loss, as if such amounts were paid in cash. Convertible Instruments U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable ASC 480-10. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. Derivative Financial Instruments The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company's control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants, if any, and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company's free standing derivatives consist of embedded conversion options with issued convertible notes. The Company evaluated these derivatives to assess their proper classification in the condensed consolidated balance sheets as of March 31, 2016 using the applicable classification criteria enumerated under ASC 815-Derivatives and Hedging. The Company determined that certain embedded conversion features do not contain fixed settlement provisions. The convertible notes contain a conversion feature such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the debt derivatives which do not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period. Recent Accounting Pronouncements There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company's financial position, results of operations or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
NOTE 4 - FAIR VALUE OF FINANCIAL INSTRUMENTS	The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable based on an entity's own assumptions, as there is little, if any, related market activity (for example, cash flow modeling inputs based on assumptions) Financial liabilities as of March 31, 2016 measured at fair value on a recurring basis are summarized below: March 31, 2016 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liabilities $ 51,828 $ -- $ -- $ 51,828 The Company determined that certain conversion option related to convertible notes issued did not have fixed settlement provisions and are deemed to be derivative financial instruments, since the exercise price was subject to adjustment based on certain subsequent equity transactions that would change the exercise price, the Company elected to use a lower reset provision. Accordingly, the Company was required to record such conversion option as a derivative liability and mark such derivative to fair value each reporting period. Such instrument was classified within Level 3 of the valuation hierarchy. For the purpose of calculating the potential embedded derivatives, the Company utilized an estimated conversion price of $0.05 (or $0.10 floor as is the case with one note) in estimating the fair value of the conversion option. The fair value of the conversion option was calculated using a binomial lattice formula with the following range of assumptions during the three and six months ended March 31, 2016: At Inception March 31, 2016 Common Stock Estimated Fair Value $ 0.05 $ 0.05 Conversion Price per Share 0.05-0.10 0.05-0.10 Conversion Shares 3,125,000 3,125,000 Call Option Value 0.0104 to 0.0226 0.007 to 0.022 Dividend Yield 0.00 % 0.00 % Volatility 120.0 % 120.0 % Risk-free Interest Rate 0.68 % 0.39 % Contractual Term 0.75 to 1.00 years 0.52 to 0.94 years In the opinion of management, there is not a sufficient viable market for the Company's common stock to determine its fair value, therefore management considers recent sales of its common stock to independent qualified investors Since the valuation model inputs are not fixed, management has estimated the fair value to be utilizing a binomial lattice model. Considerable management judgment is necessary to estimate the fair value at each reporting period. Accordingly, actual results could vary significantly from management's estimates. Conversion price per share and conversion shares are based on the lower of reset or floor price of the respective notes. The risk-free interest rate is the United States Treasury rate on the measurement date having a term equal to the remaining contractual life of the instrument. Since the Company's stock has not been publicly traded with significant volume, the Company is utilizing an expected volatility based on a review of historical volatilities over a period of time equivalent to the expected life of the instrument being valued of similarly positioned public Companies within. The dividend yield is 0% as the Company has not made any dividend payment and has no plans to pay dividends in the foreseeable future. Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivative liabilities. Level 3 financial liabilities consist of the derivative liabilities for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility or interest free rate, in isolation, can significantly increase or decrease the fair value of the derivative liabilities. Changes in the values of the derivative liabilities are recorded as a component of other income (expense) on the Company's condensed consolidated statements of operations and comprehensive loss. The following table sets forth a summary of the changes in the fair value of the Company's Level 3 financial liabilities that are measured at fair value on a recurring basis for the six months ended March 31, 2016: Balance - Beginning of period $ - Aggregate fair value of derivative instruments issued 56,949 Change in fair value of derivative liabilities (5,121 ) Balance - End of period $ 51,828

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
NOTE 5 - CONVERTIBLE NOTES PAYABLE	On January 5, 2016, the Company issued an unsecured convertible promissory note, in the principal amount of $112,500 which bears interest at 10% per annum and matures 9 months from the date of issuance. The total net proceeds the Company received from this note was $100,000, net of fees and original interest discount ("OID") of $12,500. The note will be convertible at the option of the holder at any time into shares of common stock, at an initial conversion price equal to $0.35, subject to adjustment. In the event the market capitalization (as defined) falls below $10,000,000 at any time, then in such event (a) the initial conversion price for all conversions occurring after the first date of such occurrence shall equal the lower of the initial conversion price and the market price (as defined below) as of any applicable date of conversion, and (b) the true-up provisions described below shall apply to all conversions that occur after the first date the market capitalization falls below $10,000,000. The conversion price of the note is subject to full ratchet and anti-dilution adjustment for subsequent lower price issuances by the Company, as well as customary adjustments provisions for stock splits, stock dividends, recapitalizations and the like. Beginning on the six month anniversary of the closing date and continuing on the same day of each successive month thereafter, the Company must prepay $28,750, plus all accrued interest thereon, either in cash or in common stock, at the option of the Company (each, an "Installment Amount"). If the Note is prepaid in shares of common stock, such shares shall be issued at a 40% discount of the lowest closing bid price for the 20 consecutive trading days immediately preceding the applicable redemption date, subject to a floor of $0.10 (the "Market Price"). These certain conditions were deemed to be outside the Company's control. On March 8, 2016, the Company issued a convertible promissory note with aggregate principal amount of $100,000 for an aggregate purchase price of $100,000. The note bears interest at 12% per annum and matures one year from the date of issuance. The note will be convertible at the option of the Investor at any time into shares of common stock, at an initial conversion price equal to $0.20, subject to certain anti-dilutive (reset) provisions. These anti-dilutive conditions were deemed to be outside the Company's control. The Company identified an embedded derivative related to a conversion option in the above described notes. The accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivative as of the inception date of the notes and to fair value the derivative as of each subsequent reporting date. At the inception of the notes, the Company determined the aggregate fair value of the embedded derivatives to be $56,949. For the sole purpose of calculating the potential embedded derivatives, the Company elected to use a lower reset or floor conversion price of $.05 and $0.10, respectively, to calculate the fair value. On May 12, 2016, as part of the agreement with Amarantus Diagnostics, Inc., (see Note 9) the Company has the right to offset the $100,000 promissory note due to Amarantus BioScience Holdings, for the assumption of certain liabilities and expenses in connection with the transaction. The Company has issued debt for which total proceeds were allocated to individual instruments based on the fair value of the each instrument at the time of issuance. Such value of the debt was recorded a discount on debt and is being amortized over the term of the respective debt. For the six months ended March 31, 2016 and 2015 amortization of debt discount was $10,439 and $-0-, respectively.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
NOTE 6 - STOCKHOLDERS' EQUITY	Common Stock During the six months ended March 31, 2016, the Company sold 4,700,000 restricted shares of common stock to certain investors for a total of $235,000. During the six months ended March 31, 2016, the Company issued an aggregate of 745,000 restricted shares of common stock for consulting services for a fair value of $49,750. An aggregate of 600,000 of these shares vest over a one-year period. During the six months ended March 31, 2016, the Company issued an aggregate of 45,000 restricted shares of common stock for legal services for a fair value of $2,250. On March 24, 2016, the Company issued an aggregate of 200,000 restricted shares of common stock to the two independent professionals to serve as Board of Directors for a fair value of $10,000. These shares vest over a one-year service period. On March 24, 2016, the Company issued an aggregate of 8,569,800 restricted shares of our common stock for satisfaction of certain accrued liabilities and payroll due to an officer aggregating $428,490.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
NOTE 7 - COMMITMENTS AND CONTINGENCIES	Legal In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are deemed material to the condensed consolidated financial statements as of March 31, 2016, except as discussed below. On January 13, 2014, Plaintiff Tamarin Lindenberg sued Arrayit, the Company, John Howell, Steven Scott and Gregg Linn in Civil Action No. L7698-13. Plaintiff alleged violations of the New Jersey Conscientious Employee Protection Act NJSA 34:19-1 to NJSA 34:19-8 ("CEPA"), breach of contract, breach of covenant of good faith and fair dealing, economic duress and intentional infliction of emotional distress. On August 6, 2014, the District Court dismissed Plaintiff's complaint against Arrayit for failure to state a claim upon which relief may be granted and against John Howell for lack of jurisdiction. The Company and its officers remain as defendants in the action. The Company and its officers have mounted a vigorous defense against these claims and believe they are without legal merit. As of the date of this filing , a range of potential loss is not estimatable.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
NOTE 8 - RELATED PARTY TRANSACTIONS	The Company leases corporate office space under a month-to-month operating lease of $200 per month from an entity controlled by the Company's Chief Executive Officer. For the three and six months ended March 31, 2016 and March 31 2015, total rent expense was $600 and $1,200, respectively. The Company had accrued expenses due to current and former officers, consisting mainly of salary. As of March 31, 2016 and September 30, 2015, accrued expenses due to officers were $90,217 and $141,717, respectively.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
NOTE 9 - SUBSEQUENT EVENTS	Amarantus Diagnostic, Inc. acquisition On May 11, 2016, the Company entered into a Share Exchange Agreement with Amarantus Biosciences Holdings, Inc. (“Shareholder”) to purchase 100% of the outstanding capital stock of Amarantus Diagnostics, Inc. ("AMDX"). The Company paid an aggregate consideration of 80,000,000 shares of its common stock and a $50,000 convertible promissory note for the AMDX Acquisition, subject to the issuance of additional shares upon the occurrence of certain events set forth in the Share Exchange Agreement. Each share of Avant common stock issued in connection with the AMDX Acquisition shall be subject to a lock-up beginning on the May 11, 2016 and ending on the earlier of (i) eighteen (18) months after such date or (ii) a Change in Control (as defined in the Exchange Agreement) or (iii) written consent of the parties to that certain escrow agreement entered into between the Company, AMDX, the Shareholder and certain creditors of the Shareholder. The convertible promissory note issued bears interest at 12% per annum and matures one year from the date of issuance. The note will be convertible at the option of the Investor at any time into shares of common stock, at an initial conversion price equal to $0.20, subject to adjustment. On May 12, 2016, as part of the agreement with Amarantus Diagnostics, Inc., the Company has the right to offset the $100,000 promissory note due to Amarantus BioScience Holdings, for the assumption of certain liabilities and expenses in connection with the transaction. Theranostics Health, Inc. acquisition On May 11, 2016, the Company entered into an Asset Purchase Agreement with Theranostics Health, Inc. ("THI"). The Company purchased substantially all of the assets related to THI's business and assumed certain liabilities. The Company paid an aggregate consideration of 25,000,000 shares of its common stock for the THI acquisition. Each share of Avant common stock issued in connection with the THI Acquisition shall be subject to a lock-up beginning on May 11, 2016 and ending on the earlier of (i) eighteen (18) months after such date or (ii) a Change in Control (as defined in the Exchange Agreement) or (iii) written consent of the Company, at the Company's sole discretion. As of the filing of this report, the company has not yet determined the accounting for the AMDX and THI transaction, and pro-forma information is not yet available. On May 5, 2016, the Company sold 1,500,000 shares of our common stock to certain investors for a total of $75,000. On May 5, 2016, the Company issued 200,000 restricted shares of common stock for a finder's fee to a certain Director.

SIGNIFICANT ACCOUNTING POLICI16

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Mar. 31, 2016
Significant Accounting Policies Policies
Principles of Consolidation	The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, ALP. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates include the valuation of derivative liabilities, useful lives of long-lived assets, the valuation of debt and equity instruments and the valuation allowance relating to stock based compensation and the Company's deferred tax assets. Actual results could differ from those estimates.
Net Loss Per Share of Common Stock	The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period, and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the "treasury stock" and/or "if converted" methods as applicable. The computation of basic and diluted loss per share for the six months ended March 31, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: March 31, 2016 March 31, 2015 Shares issued upon conversion of convertible notes 3,125,000 -
Intangible Assets	The Company's intangible assets consist of intellectual property for the technology transfer agreement and licensing payments for use of various patent for its worldwide exclusive licensed rights to OvaDx, a diagnostic screening test for the early detection of ovarian cancer. As of March 31, 2016 the Company has not yet received FDA approval with respect to the clinical use of these intangible assets. Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company's intangible asset with a finite life is the patent costs, which are being amortized over their economic or legal life, whichever is shorter. The estimated life is 15 years, amortized ratably. To date, these patent costs are due to legal, filing issuance and maintenance fees associated with the patents. The amortization expense was $5,379 and $15,379 for the three and six months ended March 31, 2016, respectively.
Impairment of Long-Lived Assets	The Company reviews the carrying value of intangibles and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair value. Management performed an evaluation of its intangible assets as of March 31, 2016 and no impairment was deemed to exist. Considerable management judgment is necessary to estimate the fair value. Accordingly, actual results could vary significantly from management's estimates.
Stock-Based Compensation	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the condensed consolidated statements of operations and comprehensive loss, as if such amounts were paid in cash.
Convertible Instruments	U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable ASC 480-10. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
Derivative Financial Instruments	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company's control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants, if any, and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company's free standing derivatives consist of embedded conversion options with issued convertible notes. The Company evaluated these derivatives to assess their proper classification in the condensed consolidated balance sheets as of March 31, 2016 using the applicable classification criteria enumerated under ASC 815-Derivatives and Hedging. The Company determined that certain embedded conversion features do not contain fixed settlement provisions. The convertible notes contain a conversion feature such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the debt derivatives which do not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period.
Recent Accounting Pronouncements	There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company's financial position, results of operations or cash flows.
Subsequent Events	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

SIGNIFICANT ACCOUNTING POLICI17

SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Mar. 31, 2016
Significant Accounting Policies Tables
Net loss per share of common stock	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: March 31, 2016 March 31, 2015 Shares issued upon conversion of convertible notes 3,125,000 -

FAIR VALUE OF FINANCIAL INSTR18

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
	Mar. 31, 2016
Fair Value Of Financial Instruments Tables
Summary of financial liabilities	Financial liabilities as of March 31, 2016 measured at fair value on a recurring basis are summarized below: March 31, 2016 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liabilities $ 51,828 $ -- $ -- $ 51,828
Fair value of the conversion option	The fair value of the conversion option was calculated using a binomial lattice formula with the following range of assumptions during the three and six months ended March 31, 2016: At Inception March 31, 2016 Common Stock Estimated Fair Value $ 0.05 $ 0.05 Conversion Price per Share 0.05-0.10 0.05-0.10 Conversion Shares 3,125,000 3,125,000 Call Option Value 0.0104 to 0.0226 0.007 to 0.022 Dividend Yield 0.00 % 0.00 % Volatility 120.0 % 120.0 % Risk-free Interest Rate 0.68 % 0.39 % Contractual Term 0.75 to 1.00 years 0.52 to 0.94 years
Fair value of the Company's Level 3 financial liabilities	The following table sets forth a summary of the changes in the fair value of the Company's Level 3 financial liabilities that are measured at fair value on a recurring basis for the six months ended March 31, 2016: Balance - Beginning of period $ - Aggregate fair value of derivative instruments issued 56,949 Change in fair value of derivative liabilities (5,121 ) Balance - End of period $ 51,828

GOING CONCERN AND MANAGEMENT'19

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015
Going Concern And Managements Liquidity Plans Details Narrative
Accumulated deficit	$ (10,246,366)		$ (10,246,366)		$ (9,814,078)
Net loss	$ (234,753)	$ (820,218)	(432,288)	$ (981,186)
Net cash used by operating activities			$ (189,301)	$ (119,332)

SIGNIFICANT ACCOUNTING POLICI20

SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Significant Accounting Policies Details
Shares issued upon conversion of convertible notes	3,125,000

SIGNIFICANT ACCOUNTING POLICI21

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2016	Mar. 31, 2015
Significant Accounting Policies Details Narrative
Amortization expense	$ 5,379	$ 15,379

FAIR VALUE OF FINANCIAL INSTR22

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Derivative liabilities	$ 51,828
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Derivative liabilities
Significant Other Observable Inputs (Level 2) [Member]
Derivative liabilities
Significant Unobservable Inputs (Level 3) [Member]
Derivative liabilities	$ 51,828

FAIR VALUE OF FINANCIAL INSTR23

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) - $ / shares	3 Months Ended	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2016
Common Stock Estimated Fair Value	$ 0.05	$ 0.05
Conversion Shares	3,125,000	3,125,000
Dividend Yield	0.00%	0.00%
Volatility	120.00%	120.00%
Risk-free Interest Rate	0.68%	0.39%
Minimum [Member]
Conversion Price per Share	$ 0.05	$ 0.05
Call Option Value	$ 0.0104	$ 0.007
ContractualTerm	9 months	6 months 7 days
Maximum [Member]
Conversion Price per Share	$ 0.10	$ 0.10
Call Option Value	$ 0.0226	$ 0.022
ContractualTerm	1 year	11 months 9 days

FAIR VALUE OF FINANCIAL INSTR24

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 2) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Fair Value Of Financial Instruments Details 2
Balance - Beginning of period
Aggregate fair value of derivative instruments issued			$ 56,949
Change in fair value of derivative liabilities	$ (5,121)		(5,121)
Balance - End of period	$ 51,828		$ 51,828

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Convertible Notes Payable Details Narrative
Amortization of debt discounts	$ 10,439

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative)	6 Months Ended
	Mar. 31, 2016USD ($)shares
Sale of common stock, Amount	$ 235,000
Issuance of restricted common stock consulting services, Shares | shares	745,000
Issuance of restricted common stock consulting services, Amount	$ 49,750
Issuance of restricted common stock legal services, Shares | shares	45,000
Issuance of restricted common stock legal services, Amount	$ 2,250
Common Stock
Sale of common stock, Shares | shares	4,700,000
Sale of common stock, Amount	$ 48

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015
Related Party Transactions Details Narrative
Rent expenses	$ 600	$ 1,200	$ 600	$ 1,200
Due to related party	$ 90,217		$ 90,217		$ 141,717